Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Trial to Assess the Safety and Efficacy of Burosumab in a Single Patient With Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)

NCT03993821 is registered in ClinicalTrials.gov with Laura Tosi as lead sponsor.

NCT NCT03993821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03993821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Trial to Assess the Safety and Efficacy of Burosumab in a Single Patient With Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
Lead sponsor
Laura Tosi
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2019
Completion date
March 3, 2026
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous skeletal hypophosphatemia syndrome (cshs), epidermal nevus syndrome